Company co-founded by Lemke Lab team members plans to enter stock market

The press release announces that VERAXA Biotech AG, a Swiss biopharmaceutical company co-founded by members of the Lemke Lab team, plans to go public through a merger with Voyager Acquisition Corp., a U.S.-based SPAC. This business combination, which values VERAXA at approximately $1.3 billion pre-money and $1.64 billion post-merger, will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX.” The company specializes in next-generation cancer therapies, including antibody-drug conjugates and bispecific T-cell engagers, with a robust pipeline of nine programs. The transaction, expected to close in Q4 2025, aims to provide up to $253 million in funding to advance VERAXA’s clinical and preclinical programs.